Roflumilast Foam 0.3% Secures FDA Primary Approval to Treat Seborrheic Dermatitis

Roflumilast Foam 0.3% Secures FDA Primary Approval to Treat Seborrheic Dermatitis

Arcutis Biotherapeutics today announced the FDA approval of roflumilast foam 0.3% (ZORYVE) for the treatment of seborrheic dermatitis in patients aged 9 years and older.1 Notably, roflumilast foam 0.3% is …

Read more

Compounders: Don’t Listen to the Bad Press on GLP-1s

Compounders: Don't Listen to the Bad Press on GLP-1s

While glucagon-like peptide-1(GLP-1)agonists for diabetes and weight loss remain in short supply, some clinicians are turning to compounding pharmacies to fill prescriptions. However, news reports and social media posts called …

Read more